• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 2 - Histology, Targeted Therapy and Surgery

Article

Dr Langer suggests that historically, there's been a monolithic approach to treating NSCLC.

Dr Langer suggests that historically, there’s been a “monolithic approach” to treating NSCLC. “The histologic distinctions have really come to the forefront now in advanced disease, whereas perhaps 8 to 10 years ago it didn’t really make much of a difference,” he says, “so we are holding our pathologists’ ‘feet to the fire.’”

The panel also discusses targeted therapy and surgery in treatment of NSCLC.

Dr Sugarbaker says surgery is dynamic, noting there are a number of techniques to resect or remove the tumor with technology’s help. “These have significantly reduced the morbidity or the stress and pain for the patient.”

Related Videos
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
dr joseph alvarnas
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.